Kymriah (Tisagenlecleucel)

Kymriah (Tisagenlecleucel) is an innovative cancer therapy known as CAR T-cell therapy. It uses a patient’s own immune cells, specifically T-cells, which are collected and engineered in a lab to better recognize and attack cancer cells. These modified cells are then infused back into the patient, where they target and destroy cancer, particularly certain types of blood cancers like leukemia and lymphoma. Kymriah represents a personalized approach that harnesses the body’s immune system to fight cancer more effectively.